Basecamp Research Raises $140M to Power New AI Biology Models
- Basecamp Research, a London-based AI drug design startup, closed an oversubscribed $140M Series C led by S32 at an ~$800M valuation, with Nvidia, Anthropic's Anthology Fund and other investors participating.
- Funds will train next-generation EDEN foundation models built on the firm's proprietary environmental and biodiversity genomic dataset.
- The financing advances a pipeline of AI-designed therapeutics, starting with in vivo cell therapies, toward clinical development.
💡 Points
Basecamp isn't training on the same public protein databases every AI-discovery rival uses — its moat is proprietary environmental and biodiversity genomics, genuinely hard to replicate, worth more than the $800M valuation headline. Nvidia and Anthropic both backing one biology-foundation-model shop reads as infrastructure players staking platform claims on bio FMs, and opening the pipeline with in vivo cell therapy instead of small molecules is a far riskier first bet to prove the thesis in clinic.
AI startup Basecamp Research raises $140M Series C, shares pipeline ↗